Fresenius

With our reporting and communication formats, we provide comprehensive information on our Sustainability Framework and the management of material topics. Group-wide policies enable consistent integration of sustainability considerations in daily business operations. 

In our rating overview, we present the latest scores from relevant ESG rating agencies. 

 

Publications and Policies

In our annual sustainability reporting, we disclose required regulatory information regarding our material sustainability topics. In addition, we publish our Sustainability Highlights Magazine once a year, providing an overview of our related activities.

 

Sustainability Statement 2025
in accordance with the European Sustainability Reporting Standards 

Our policies provide employees and business partners with clear guidance on our approach to responsible business conduct and sustainability. Among the relevant internal documents are:

Fresenius Group Code of Coduct

Fresenius AI-Guidelines

Group Environmental Policy

Group Human Rights Statement

Group Tax Policy

Group Social and Labor Standards Guideline

Code of Conduct for Business Partners

Rating overview

ESG rating agencies regularly evaluate and review Fresenius' sustainability performance. In doing so, they focus on different aspects across the areas of Environment, Social, and Governance (ESG). 

A close dialog with our stakeholders on these topics is very important to us. We are actively working to enhance transparency on relevant topics. This is reflected in consistently good rating results.

 

 

*The use by FRESENIUS SE & CO. KGAA of any MSCI ESG RESEARCH LLC or its affiliates (“MSCI”) data, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement, recommendation, or promotion of FRESENIUS SE & CO. KGAA by MSCI.  MSCI services and data are the property of MSCI or its information providers, and are provided ‘as-is’ and without warranty. MSCI names and logos are trademarks or service marks of MSCI.

*Copyright ©2025 Morningstar Sustainalytics. All rights reserved. The information, data, analyses and opinions contained herein: (1) includes the proprietary information of Sustainalytics and/or its content providers; (2) may not be copied or redistributed except as specifically authorized; (3) do not constitute investment advice nor an endorsement of any product, project, investment strategy or consideration of any particular environmental, social or governance related issues as part of any investment strategy; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. The ESG-related information, methodologies, tool, ratings, data, and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Neither Morningstar Inc., Sustainalytics, nor their content providers accept any liability for the use of the information, for actions of third parties in respect to the information, nor are responsible for any trading decisions, damages or other losses related to the information or its use. The use of the data is subject to conditions available at https://www.sustainalytics.com/legal-disclaimers.

RELATED CONTENT

Sustainability Human Dimension Planet Dimension Ethical Foundation Stakeholder Engagement

Our commitment to a healthy planet
As a healthcare company, we operate in a special field of tension. On the one hand, we want to do our best to reduce potentially adverse environmental impacts to a minimum. On the other hand, we must never lose sight of the strict requirements that are placed on patients’ safety and hygiene. Our aim is to promote human health while further reducing our ecological footprint. 

People need a healthy home – today and tomorrow. By reducing the environmental impact of our activities, we want to play our part in mitigating climate change and conserving natural resources. 

Quote Axel Faupel

The Planet Dimension of our Sustainability Framework encompasses the following focus topics:

We have a clear goal: to decarbonize our operations and our value chain. 

Fresenius manufactures medical products and operates healthcare facilities, which inevitably results in energy consumption and associated greenhouse gas emissions. In production, for example, the machines and containers have to be sterilized, and in our hospitals a wide variety of technical systems are in constant operation. This presents us with special challenges: On the one hand, we want to reduce our energy demand as far as possible and on the other hand, we must always guarantee the safety of patients in our facilities and ensure a stable supply of energy in our production.

We want to live up to our responsibilities and help achieve the goal of the Paris Climate Agreement: Our climate targets aim to limit global warming to 1.5 °C. All our climate protection activities contribute to our long-term objective of attaining net zero by 2050: This requires a company to reduce its avoidable greenhouse gas emissions, while unavoidable emissions must be offset by removing an equivalent amount from the atmosphere and storing it for the long term.

Within our own operations, we are committed to reducing our Scope 1 and Scope 2 emissions by 50% by 2030.
 


The decarbonization of our value chain is a decisive factor on our long-term path to net zero. Scope 3 emissions include greenhouse gases that are released indirectly in our upstream and downstream value chains – such as from purchased raw materials or at the end of the life of sold products.

Climate change is also a health issue. Rising temperatures, more frequent heatwaves and changing weather patterns directly affect people's health, particularly vulnerable groups such as the elderly, chronically ill, and children. Heat stress can lead to circulatory problems, dehydration and an increased risk of death. At the same time, climate change contributes to the spread of infectious diseases, for example by introducing new vectors such as mosquitoes or contaminating water sources. As a healthcare company, we therefore consider it our responsibility to not only react to the effects of climate change, but also actively contribute to mitigating it. After all, climate protection is health protection.
 


➔ Read more in our Sustainability Statement.

We place particular emphasis on preserving water quality. In water-stressed areas, we are especially committed to reducing our water withdrawal. 
 

 

Water is one of our most valuable resources. As a healthcare company, we are dependent on water: We need drinking water of the highest quality to ensure safe patient care. It is crucial for hygiene and well-being. We also use water in the production of our pharmaceutical products – as process water as well as product component. The quality requirements for this water are even higher than those for drinking water. 
 

Water reduction target

It is our ambition to avoid or minimize any negative impact on the environment that may arise from our direct business operations or from downstream activities. This also includes avoiding unnecessarily polluting the sources from which we obtain water or into which we discharge our wastewater.
 

➔ Read more in our Sustainability Statement.

At Fresenius, we focus on reducing our waste and embedding circular principles into product design and packaging solutions.

We are committed to conserving natural resources wherever possible. In doing so, we always have to strike a balance between resource efficiency and hygiene requirements. Disposable items are often used in clinics for hygienic reasons. Our options for saving resources are limited here. There are also strict regulations for pharmaceutical packaging. Our most important levers for conserving resources are therefore developing durable and resource-saving products, reusing resources wherever possible, and disposing of waste safely and systematically.
 


➔ Read more in our Sustainability Statement.

Sustainability Insights

Explore our stories to learn what sustainability looks like in our daily operations:

  • The journey of water in production

    Water is essential for life on earth. As a healthcare company, we also rely on clean water being readily available. Visit a production site of Fresenius Kabi to find out about the role water plays in manufacturing of our healthcare products.

    Read more

  • Climate change and health

    Climate change not only leads to an increase in extreme weather phenomena such as heat, storms, floods and flooding caused by heavy or continuous rainfall, but also increases potential health risks. 

    Read more

  • Project DOME

    Setting targets and working to become a more sustainable company is only possible if you know what you are looking at and talking about. Therefore, we, at Quirónsalud, brought a project to life that allows us to monitor the energy, water, and gas consumption of our Spanish hospitals in one system.

    Read more

  • Redesign of green spaces in Hildesheim

    Helios hospital Hildesheim is gradually redesigning its approximately 24,000 m² of outdoor areas on the hospital grounds in a sustainable manner. This includes creating biodiversity, habitats and a food supply for birds and insects as well as beautiful recreational areas for patients and staff. 

    Read more

  • Collaboration to increase efficiency

    The Global Competence Cluster Energy, Water & Waste Management was established as an additional component to the existing management systems in 2019. The aim is to offer experts at all the production sites a platform where they can share innovative ideas and proposals.

    Read more

Related Content

Sustainability Human Dimension Ethical Foundation Human Rights Stakeholder Engagement Data & Reporting Hub

We value open communication and strive to create an environment in which patients, employees, members of local communities, business partners, or other potentially affected persons can report human rights violations or non-compliance with environmental regulations. To this end, we have set up whistleblower systems.

Process for handling and investigating reports

The following graphic illustrates the steps for processing reports, starting from the acknowledgment of receipt to the feedback provided to the person filing the report, using the example of two fictional protagonists: Kate and Aditi.*

*The persons and stories depicted in this image are purely fictional. Any resemblance to actual persons is purely coincidental and unintentional.

  • 1 – Confirmation of receipt

    Kate reports a suspicion of possible misconduct through the grievance mechanism. Aditi, a specially trained member of our Business Integrity Team, receives the report and confirms its receipt.

  • 2 – Pre-Assessment

    Aditi carefully reviews the received report for plausibility and completeness. She contacts Kate to obtain additional information, if needed.

  • 3 – Preparation

    Following the initial assessment, Aditi determines that the report contains indications of a potential compliance incident related to human rights. She then defines the objective and scope of the investigation and formally issues the mandate to proceed with the investigation. Subsequently, she hands over the case to the responsible investigation team to clarify the incident.

  • 4 – Investigation

    The investigation team analyzes the facts and evaluates the underlying processes to identify potential weaknesses. It ensures that the investigation is conducted confidentially, fairly, objectively, and proportionately. All collected information, as well as the insights derived from it, are carefully documented and summarized by the investigation team.

  • 5 – Remediation

    Based on the results of the investigation, the responsible department decides which actions need to be taken to prevent similar violations in the future. These may include personnel measures as well as the introduction of process adjustments. The responsible department ensures that all corrective actions are appropriate and monitors their timely implementation. The investigation team, led by Aditi, documents this process.

  • 6 – Feedback to the reporter

    Once the investigation is concluded, Kate receives feedback on the status of the investigation and the actions taken - naturally, in compliance with confidentiality and data protection requirements.

Additional information on our grievance mechanisms and the protection of whistleblowers can be found in the process descriptions of the respective companies:

Fresenius SE:
https://www.fresenius.com/grievance-mechanism

Fresenius Kabi:
https://www.fresenius-kabi.com/responsibility/business-ethics

Fresenius Helios:
https://www.helios-gesundheit.de/menschenrechte

Quirónsalud: 
https://www.quironsalud.com/en/group/whistleblowing-channel
 

Help us do the right thing!

Have you ever had the feeling that something isn’t quite right? Perhaps you noticed something that shouldn’t be the way it is, or you yourself were affected by such a situation. That’s when it’s time to report a grievance.

Watch the video to find out how to report a grievance, to learn why reporting grievances is so important, and to see what happens to a report after you submit it.

Your information counts!

Reports received with human rights relevance in the reporting year 2025

The metrics describe the reports received through our reporting systems in the reporting year that were related to human rights – broken down into those affected in our own operations and those in our value chain. Of the 24 (2024: 28) reports received, 1 (2024: 4) proved to be a human rights violation. No report was related to a severe human rights incident in the upstream or downstream value chain or in Fresenius’ own operations.1

Own operations Value chain

Reports received with human rights relevance

23 1

Of which are violations

1 -

Of which are severe human rights violations 

 - -

  • 1Severe human rights violation include incidents of forced labor, incidents of human trafficking, incidents of child labor as well incidents involving a large number of people or affecting a large area. This categorization is based, for example, on the definitions of the Corporate Sustainability Reporting Directive (CSRD).

    The Group-wide Sustainability Report 2025 (CSRD Report) contains detailed information on the substantiated cases and the remedial and preventive measures implemented in the chapters “Own workforce” and “Workers in the value chain”.

Consideration of the interest of those affected

At Fresenius, we attach great importance to taking appropriate account of the interests of whistleblowers and those of potentially affected persons in the processing of reports. We achieve this through a transparent, fair and comprehensive examination of all incoming complaints by specially trained staff.

Our aim is to ensure that the concerns of those affected are taken seriously and processed in accordance with the applicable legal and internal company requirements. In doing so, we ensure that all relevant information and perspectives are included in the decision-making process to find a balanced and appropriate solution.

Through feedback from those affected, we analyze how our process is accepted in practice and where there is potential for optimization. This input is incorporated into the further development of our processes to ensure that the interests of those affected are taken into account even better in future.
 

Review and further development of our complaints procedure

The results of our risk analysis and the findings on potential target groups of our grievance and whistleblower channels are incorporated into the further development of our grievance mechanism and the processing of respective reports. Based on our findings, we review the effectiveness of the procedure on an annual basis, or more frequently if required. Where necessary, we make appropriate adjustments and changes with regard to accessibility and process.

Human Rights at Fresenius

Our Human Rights Program

Further Information

Group-wide Governance & Responsibilities Risk Assessment & Impact Preventive & Remedial Action

Contact

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg
Germany

humanrights@fresenius.com

Human Rights Program

Our Human Rights Program Group-wide Governance & Responsibilities Risk Assessment & Impact Preventive & Remedial Action

You want to file a report?

Reports on possible human rights violations or other types of compliance violations can be reported around the clock, either anonymously or by name, via our whistleblower system*: 

Whistleblower system
https://freseniusgroup.ethicspoint.com

By telephone*
+49 (0) 800 181 1338

By mail
Fresenius SE & Co. KGgaA Business Integrity 
Else-Kröner-Str. 1 
61352 Bad Homburg v.d.H. Deutschland 

By e-mail:
humanrights@fresenius.com 

* The prices of your mobile or landline contract apply.
 

The reporting on the respect for human rights for the year 2024 and following can be found in our Sustainability Report (CSRD Report). Further information on Fresenius' human rights program is available here: fresenius.com/en/human-rights 

Human rights risks can change over time. We therefore conduct annual and event-related risk analyses. In the 2024 reporting period, this was done in the third and fourth quarters. An event-related risk analysis was not conducted.

Remark: The results of the risk analysis for the 2025 reporting year will be updated at a later stage. 

Process for identifying and assessing human rights risks

Identifying and assessing human rights risks in our own company and in our value chain is a comprehensive process that consists of risk identification, risk analysis, and risk assessment. We follow a risk-based approach that can be divided into three phases and is explained below with the help of the fictional protagonist, John.*

*The persons and stories depicted in these images are purely fictional. Any resemblance to actual persons is purely coincidental and unintentional.

  • Risk identification

    John works in the Fresenius Human Rights team. In the first phase, he conducts a country- and industry-specific abstract risk analysis to identify potential human rights risks.

  • Gap analysis

    To evaluate which of the identified potential risks could also be actual risks, John conducts a gap analysis in the second phase. For this, he uses standardized questionnaires, for example, to record processes, responsibilities, and procedures for each potential risk area. This applies to our own business as well as to the value chain. John closely involves the risk owners and experts from the affected departments in these gap analyses.

  • Risk assessment

    In the third and final step of the risk analysis, John, together with the experts from the affected departments, analyzes and evaluates the gaps and risks identified, taking into account the impact on those affected and the likelihood of occurrence. For prioritized risks, they then define remedial and preventive measures.

Curious about how we weigh and prioritize risks? Here's how:

To weight and prioritize risks, we introduced a comprehensive methodology for assessing their impact and likelihood of occurring. Using this method, the risks are plotted on a matrix (4x4).

The evaluated impact on those affected ranges from “low” to “severe”. It is assessed using four evaluation criteria: scope, scale, possibility for remedial action, and company involvement.
Probability of occurrence ranges from “unlikely” to “almost certain”. It is assessed using three different evaluation criteria: process evaluation, evaluation of similar cases which have already arisen, and context factors which could increase the likelihood of the risks materializing.

Results of the risk analysis

We carry out a regular risk analysis of human rights topics for both our own businesses and our supply chains in accordance with the specific requirements of applicable international and national laws and regulations. As part of this risk analysis, we identify areas that we consider to have high priority due to the potential severity of possible violations and due to our ability to influence them.

Prioritized risk areas for own operations

The risk analysis for the 2024 reporting year confirmed the following existing prioritized risk areas for our own operations and revealed additional potential risks: 

  • Discrimination and unequal treatment
  • Freedom of association and collective bargaining
  • Occupational health and safety in the workplace 

Preventive measures to mitigate risks in our own operations

As a healthcare Group, we not only bear responsibility for the well-being of our patients, but also for the health and safety of our employees.  We implemented a Group Policy on Social and Labor Standards. The guideline describes our global social and labor law minimum standards. We expect our employees and managers in all business segments of the Fresenius Group to comply with this guideline without exception. Lower standards are not acceptable. Should laws or practices in countries where we operate restrict or contradict the standards set out in this policy, we will apply the policy to the extent permitted by local laws . Moreover, the Fresenius Code of Conduct stipulates that we take the necessary measures to protect our employees and prevent work-related accidents and illnesses. 

Creating a safe and healthy working environment is a priority for us. When it comes to health protection, prevention is our basic principle: We therefore provide our employees with comprehensive programs to promote their health and prevent work-related illnesses. The return of employees after an illness is regulated, for example, by the company integration management system.

We have introduced numerous management systems and measures throughout the Group and adapted them to the business models of the business segments. They focus on occupational health and safety in the production area as well as occupational health management for employees in healthcare facilities or in administration. 

All locations are also subject to the respective local regulations and laws. Compliance with these regulations is ensured at local level. In addition to statutory regulations, internal guidelines and directives such as management manuals and standard operating procedures also play a significant role in occupational health and safety. In addition to the Group-wide Fresenius Code of Conduct, the business segments have their own guidelines that regulate occupational health and safety, e.g. the Clinical Code of Conduct for the rehabilitation and nursing units and medical personnel in the healthcare services market segment.

The internal requirements are supplemented by corresponding internationally recognized standards for management systems such as ISO 45001 at some locations as well as other certifications in accordance with ISO or national standards. The overarching aim of the ISO 45001 management system is to continuously improve occupational health and safety management, align it with internationally recognized methods and ensure the effectiveness of existing procedures and systems. To drive this forward, we are consistently expanding the number of entities certified to this standard.  

Further Information can be found in the 2024 CSRD report from page 216.

To minimize potential human rights risks connected to our business activities, we have taken further preventive and mitigating measures. These include, for example, training that we offer to our workforce. The Fresenius Group, for instance, conducts regular occupational health and safety training to prevent incidents in its fields of operation.

To sustainably promote tolerance and appreciation within our teams in the long-term and to mitigate the risk of discrimination, it furthermore is not only necessary to have a corresponding culture that is exemplified by the management bodies; employees also receive training and further education on the topic of diversity. 

The elimination of discrimination is both a component of our Group-wide compliance programs and a key element of our Human Rights Program. These concepts are supplemented by suitable controls, process documentation, training concepts, awareness-raising measures, and the use of whistleblower systems. In this way, we want to ensure that discrimination, including harassment, is prevented, contained, or combated in our operational business if we become aware of violations, risks, or impacts.

Another central element is the successive roll out of a company-wide human rights training for our employees. The training aims at educating our employees on this important topic – not only about their personal human rights, but also about the contribution that everyone can make in their daily work. It further imparts knowledge about individual rights and how to deal with possible human rights violations. 
 

In addition, we have implemented individual and local measures to provide our employees with the best possible protection within our sphere of influence. For instance, at high-risk locations, we deploy more security staff than is typically found in hospitals to better protect our employees and patients around the clock. Furthermore, a monthly committee with participants from local management and employees has been established to strengthen the dialogue.

Further details on preventive and remedial measures, as well as on appropriateness and effectiveness, are available here.
 

Prioritized risk areas for our value chain

The risk analysis for the 2024 reporting year confirmed the following existing prioritized risk areas for our value chain and revealed additional potential risks: 

  • Remuneration and appropriate compensation
  • Discrimination and unequal treatment
  • Environmental pollution
  • Freedom of association and collective bargaining
  • Occupational health and safety in the workplace

Preventive measures to mitigate risks across our value chain

To counter the potentially negative effects, we have initiated and implemented further preventive measures in addition to existing ones. With the risk-based implementation of human rights and environmental clauses in contracts, we also agree with suppliers on specific requirements for cooperation and information obligations in the event of human rights violations. 

Our Code of Conduct for Business Partners also sets out fundamental expectations regarding respect for human rights. To monitor compliance with these principles and use the results to provide industry-wide support, Fresenius Kabi, for example, prepared to join the Pharmaceutical Supply Chain Initiative (PSCI) as an associate member in the reporting year (2024). In the future, the company will participate in the industry-wide audit pooling and thus contribute to greater transparency regarding working conditions and – where necessary – corresponding corrective or remedial measures in the pharmaceutical supply chain.

“Our membership in the Pharmaceutical Supply Chain Initiative reflects our commitment to shared responsibility, ethical sourcing, and collaboration — all essential to driving respect for human rights across our value chain.”

Marco Kraemer,  Director Supplier Quality Management & Human Rights Function, Fresenius Kabi

To further increase transparency in our upstream and downstream processes, we also plan to further expand the existing descriptions and visualizations of our value chains and carry out focus risk analyses on this basis. Further details on preventive and remedial measures, as well as on appropriateness and effectiveness, are available here.

Human Rights at Fresenius

Our Human Rights Program

Further Information

Group-wide Governance & Responsibilities Preventive & Remedial Action Grievance Procedure & Handling

Contact

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg
Germany

humanrights@fresenius.com

Human Rights Program

Our Human Rights Program Group-wide Governance & Responsibilities Preventive & Remedial Action Grievance Procedure & Handling

Whistleblowing system

Reports on possible human rights or other types of compliance violations can be reported around the clock, either anonymously or by name, via our whistleblower system*:

Phone number: +49 (0) 800 181 1338*
https://freseniusgroup.ethicspoint.com

More infos about our grievance mechanism

*The prices of your mobile or landline contract apply

The reporting on the respect for human rights for the year 2024 and following can be found in our Sustainability Report (CSRD Report). Further information on Fresenius' human rights program is available here: fresenius.com/en/human-rights

S&P Global Ratings (S&P), a globally recognized credit rating agency today revised its credit outlook for Fresenius SE from stable to positive. The rating was affirmed at BBB. As part of its evaluation, S&P acknowledged the significant progress highlighting Fresenius’ strong operating performance, particularly within its growth vectors, ongoing cost base improvements, as well as a further reduction in the Company’s leverage. S&P also highlighted the sharpened and simplified portfolio, underscoring the Company’s resilience in the current operating environment.

“The revised outlook is another proof point that #FutureFresenius is paying off. It confirms our focus on long-term profitable growth and balance sheet strength, while at the same time preparing the business for future growth. Based on the strength of our operating businesses and the strong cash flow generation, we have significantly deleveraged the Company over the past years and expect to stay well within our self-imposed target leverage range,” says Fresenius CFO Sara Hennicken.

Fresenius is rated investment grade by the three leading credit rating agencies S&P Global Ratings (BBB/positive), Moody’s (Baa3/stable) and Fitch (BBB-/stable). The company is committed to its investment grade rating and to its self-imposed target leverage range of 2.5 to 3.0x net debt/EBITDA1, which forms part of its capital allocation framework.

1 At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures; before special items; including lease liabilities and Fresenius Medical Care dividend, net debt adjusted for the valuation effect of the exchangeable bond

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852 
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE 
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673 Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser 
Chairman of the Supervisory Board: Wolfgang Kirsch

S&P Global Ratings (S&P), a globally recognized credit rating agency today revised its credit outlook for Fresenius SE from stable to positive. The rating was affirmed at BBB. As part of its evaluation, S&P acknowledged the significant progress highlighting Fresenius’ strong operating performance, particularly within its growth vectors, ongoing cost base improvements, as well as a further reduction in the Company’s leverage. S&P also highlighted the sharpened and simplified portfolio, underscoring the Company’s resilience in the current operating environment.

“The revised outlook is another proof point that #FutureFresenius is paying off. It confirms our focus on long-term profitable growth and balance sheet strength, while at the same time preparing the business for future growth. Based on the strength of our operating businesses and the strong cash flow generation, we have significantly deleveraged the Company over the past years and expect to stay well within our self-imposed target leverage range,” says Fresenius CFO Sara Hennicken.

Fresenius is rated investment grade by the three leading credit rating agencies S&P Global Ratings (BBB/positive), Moody’s (Baa3/stable) and Fitch (BBB-/stable). The company is committed to its investment grade rating and to its self-imposed target leverage range of 2.5 to 3.0x net debt/EBITDA1, which forms part of its capital allocation framework.

1 At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures; before special items; including lease liabilities and Fresenius Medical Care dividend, net debt adjusted for the valuation effect of the exchangeable bond

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852 
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE 
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673 Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser 
Chairman of the Supervisory Board: Wolfgang Kirsch

All

Category

Annual Reports Quarterly Financial Reports Presentations

Time span

Annual Reports

Quarterly Financial Reports

Presentations

0
All

Events

Capital Markets Day Conferences Financial Reporting Roadshows

Time span

Home

FRESENIUS SE & CO. KGaA

 

 

 

News

  • #FutureFresenius is paying off: S&P Global Ratings revises outlook for Fresenius SE from stable to positive

    #FutureFresenius is paying off: S&P Global Ratings revises outlook for Fresenius SE from stable to positive

    S&P Global Ratings (S&P), a globally recognized credit rating agency today revised its credit outlook for Fresenius SE from stable to positive.

    April 08, 2026 · Fresenius

  • Brief News

    Fresenius publishes 2025 Annual Report – REJUVENATE: Delivering accelerated performance for long-term value creation

    Today, Fresenius published its 2025 Annual Report. As announced in late February 2026, 2025 marked another strong year of performance and the launch of the current phase of the #FutureFresenius strategy: Rejuvenate. Despite headwinds, the healthcare group achieved its outlook, which was raised twice during the year. Group revenue before special items rose to €22.6 billion, with organic growth of 7%, while constant currency Core EPS (excluding FMC) increased by 12%. “Over the past three years, we have successfully implemented our #FutureFresenius strategy and created a new Fresenius that is innovative, relevant, resilient, and adaptable. At the same time, we have significantly bolstered our company’s economic strength. We aim to build on this strong foundation,” said Michael Sen, Chairman of the Management Board of Fresenius. The 2025 Annual Report demonstrates how Fresenius is creating sustainable value for all stakeholders by executing its #FutureFresenius strategy. It includes the Sustainability Statement in accordance with the European Sustainability Reporting Standards (ESRS), and is available as a PDF and as an interactive online version in German and English. The online report features additional business stories and includes a video statement from CEO Michael Sen.

     

    March 25, 2026 · Fresenius

    #FutureFresenius: REJUVENATE in action – Delivering accelerated performance for long-term value creation; 2025 yet another year of strong delivery

    #FutureFresenius: REJUVENATE in action – Delivering accelerated performance for long-term value creation; 2025 yet another year of strong delivery

    February 25, 2026 · Fresenius

  • Fresenius Supervisory Board extends ahead of schedule CEO Michael Sen’s contract by five years --- Christian Pawlu to join Management Board for Fresenius Helios effective July 1, 2026

    Fresenius Supervisory Board extends ahead of schedule CEO Michael Sen’s contract by five years --- Christian Pawlu to join Management Board for Fresenius Helios effective July 1, 2026

    The Fresenius Supervisory Board has unanimously extended ahead of schedule the mandate of CEO Michael Sen (57) by five years. This will help to ensure continuity in the company’s leadership for the next phase in its #FutureFresenius strategy. His contract will now run until 2031.Wolfgang Kirsch, Chair of the Supervisory Board of Fresenius, said: “Michael Sen has been instrumental in driving the company’s development with #FutureFresenius in the past three years. Today, Fresenius is more innovative and relevant – well positioned to leverage the significant opportunities in the healthcare industry. Michael Sen and his team have placed Fresenius on a growth path offering long-term profitability that benefits all stakeholders. We want to maintain this continuity. Both the Supervisory Board and I personally look forward to continuing our collaboration in the coming years.”“I would like to thank the Supervisory Board for its trust and look forward to continuing to work with all Supervisory Board members, my management team, and our outstanding employees as well as our customers, partners, and shareholders. Over the past few years, we have made the company more innovative while remaining focused on delivering profitable growth. Today, Fresenius is more relevant than ever before. We want to continue this success story. In times of fundamental change shaped by rapid advances in new technologies such as AI and a transactional world order, we bear even greater responsibility as a leading global healthcare company. Now more than ever, our goal is to provide high-quality, reliable healthcare while making healthcare systems even more efficient and resilient,” adds Michael Sen, CEO of Fresenius.Dr. Christian Pawlu succeeds Robert MöllerThe Fresenius Supervisory Board has also unanimously appointed Dr. Christian Pawlu (48) to the Fresenius Management Board, effective July 1, 2026. He will oversee the businesses of Fresenius Helios, which includes the two private hospital chains, Quirónsalud in Spain and Helios Kliniken in Germany. He will succeed Robert Möller (59) on the Management Board, who will establish the company’s Office of the Management in Berlin and Brussels.“On behalf of the Supervisory Board, I would like to sincerely thank Robert Möller for the excellent cooperation and successful leadership of Fresenius Helios in recent years. Through the formation of medical clusters and the focus on digitalization and excellent patient care, the two hospital chains are excellently positioned in Germany and Spain. I am therefore delighted that Robert Möller will continue to contribute his expertise to the company,” says Wolfgang Kirsch. He adds: “With Christian Pawlu, we have been able to acquire a physician and strategist with a broad international network for the Group’s Management Board. I am especially pleased that we could find an outstanding internal candidate who has already contributed significantly to the hospital business as Chief Operating Officer of Fresenius Helios. I wish Christian Pawlu a strong start in his new role.”Michael Sen (57) has been CEO of Fresenius since October 1, 2022. He is also Chairman of the Supervisory Board of the listed dialysis provider Fresenius Medical Care. In April 2021, Michael Sen was appointed CEO of Fresenius Kabi. Before joining Fresenius, he was a member of the Management Board at Siemens AG, responsible for the healthcare and energy business. He took Siemens Healthineers public during this time. Prior to this, he was Chief Financial Officer at the energy group E.ON SE.Dr. Christian Pawlu has been Chief Operating Officer (COO) of Helios in Germany since March 2025, and in September 2025 expanded his responsibilities as COO of Fresenius Helios including Helios in Germany and Quirónsalud in Spain. Prior to this, he served as Head of Corporate Development at Fresenius after joining Fresenius Kabi in Bad Homburg as Head of Corporate Development in April 2021. From 2022 to 2025, he was a member of the Supervisory Board of the Fresenius subsidiary mAbxience, based in Spain. In his early career, Christian Pawlu was a member of Sandoz Group AG’s Executive Board, CEO of a private high-tech start-up, and a partner at McKinsey & Company management consultancy.

    February 25, 2026 · Fresenius

  • Brief News

    Fresenius and Phlow Partner to Strengthen U.S. Supply of Essential Medicine

    Fresenius Kabi, an operating company of Fresenius, has entered a first-of-its-kind partnership with U.S. manufacturer Phlow Corp. to establish a fully domestic, end-to-end supply chain for Epinephrine Injection, USP — an FDA designated essential medicine frequently at risk of shortage in the United States. Under the collaboration, Phlow will produce the U.S.-based API, while Fresenius Kabi manufactures the finished doses for hospitals and clinics across the country. With this initiative, Fresenius advances its local-for-local manufacturing strategy and supports national efforts to strengthen pharmaceutical security. The partnership reinforces the ambitions of #FutureFresenius as it expands Fresenius’ role as a leading global provider of lifesaving therapies, advancing resilient manufacturing that improves patient care and health-system stability. Pending regulatory approvals, epinephrine produced through this collaboration could be available to U.S. hospitals in 2027.

     

    February 09, 2026 · Fresenius Kabi

    AI in Healthcare: SAP and Fresenius Accelerate Digital Healthcare Delivery

    AI in Healthcare: SAP and Fresenius Accelerate Digital Healthcare Delivery

    January 19, 2026 · Fresenius

  • Brief News

    Fresenius advances scalable cell therapy manufacturing with strategic-development agreement

    Fresenius has entered into a strategic development agreement with TQ Therapeutics to support the scalable and efficient manufacturing of cell and gene therapies, strengthening its role in advancing next generation treatments. Under the agreement, operating company Fresenius Kabi receives an exclusive license to integrate TQ Therapeutics’ proprietary cell selection technology into its Cue® Cell Processing System. The combined solution aims to isolate high purity T cells in less than two hours, helping therapy developers streamline processes and accelerate development. The collaboration is in line with Fresenius’ #FutureFresenius strategy to focus on high value healthcare platforms, strengthen core technologies, and improve patient access through operational excellence and innovation. By enabling more automated, robust, and scalable cell therapy manufacturing, Fresenius Kabi and TQ Therapeutics aim to support the broader adoption of cell and gene therapies, including applications closer to the point of care.

     

    January 14, 2026 · Fresenius Kabi

    Brief News

    Sale of Austrian project business and spa operations to PORR approved

    The sale of the Austrian project business and spa operations of VAMED Vitality World to PORR, announced by Fresenius in October 2025, has received the necessary approvals and will be completed on December 31, 2025. 

     

    December 23, 2025 · Fresenius

  • Brief News

    Fresenius strengthens biomanufacturing capabilities through AI collaboration

    mAbxience, a Fresenius entity, has entered into a collaboration with HP Inc. to develop an artificial intelligence (AI) solution aimed at making biomanufacturing more efficient and reliable.The joint project uses AI and digital-twin technology to model and optimize key steps in the production of monoclonal antibodies and biosimilars. By simulating critical cell-culture parameters and predicting process outcomes, the system is designed to support more consistent yields, faster development cycles, and better control of large-scale manufacturing environments. This is a showcase of Fresenius’ pathway in leveraging AI and digital solutions, from production and supply-chain to care delivery, improving treatment quality, and expanding access to state-of-the-art therapies. Both partners view the technology as a significant step toward more data-driven and tightly managed bioproduction. The prototype, developed with real manufacturing data and validated in an industrial setting, enables teams to test scenarios virtually before applying them on the shop floor.This initiative is the first project under a broader strategic framework between HP and mAbxience at its manufacturing facility in Leon, Spain, and has the potential to be rolled out across additional sites. It represents another milestone in advancing Fresenius’ (Bio)Pharma platform and supports the goals of #FutureFresenius.Fresenius in SpainThe global healthcare company Fresenius is deeply rooted in Spain. With Quirónsalud, the country’s leading hospital operator, and Fresenius Kabi, offering essential medicines and technologies for critically and chronically ill patients, the company makes a decisive difference in the life-quality of Spanish citizens. With the majority acquisition of mAbxience in 2022, Fresenius created a dedicated and vertically integrated biosimilars development and manufacturing platform. In line with its #FutureFresenius strategy, the company is further scaling in (Bio)Pharma to deliver simplification and drive efficiencies, underscoring its commitment to offering accessible, innovative, and high-quality healthcare solutions.

     

    December 04, 2025 · Fresenius Kabi

    Brief News

    Fresenius Launches Denosumab Biosimilars in EU

    Fresenius announced today the launch of its denosumab biosimilars, Conexxence®1 (denosumab) and Bomyntra®2 (denosumab), in Europe. These biosimilars received approval from the European Commission in July 2025 for all indications of the reference products Prolia®3 (denosumab) and Xgeva®4 (denosumab), respectively. “Being the first biosimilar company with a pre-filled syringe for the denosumab oncology indication in Europe, showcases our commitment to offering new treatment options that support patient care and affordability across Europe,” said Dr. Sang Jin Pak, President Biopharma. This milestone marks the next step in the company’s ambition to drive accessibility to high-quality biosimilar therapies, with multiple molecules in early and late-stage development. By continuing its successful track record in the biosimilars space, Fresenius further strengthens its (Bio)Pharma platform, a key pillar of the #FutureFresenius strategy. 1. Conexxence® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.  2. Bomyntra® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.  3. Prolia® is a registered trademarks of Amgen Inc.  4. Xgeva® is a registered trademarks of Amgen Inc.

     

    December 01, 2025 · Fresenius Kabi

  • Katrin Kerner and Christian Wagner to lead Group Communications at Fresenius

    Katrin Kerner and Christian Wagner to lead Group Communications at Fresenius

    Effective immediately, Katrin Kerner (44) and Christian Wagner (39) will assume joint leadership of Group Communications at Fresenius. Both will assume the role on an interim basis and in addition to their current responsibilities as Head of CEO Relations and Head of Board Office. They will report directly to Fresenius CEO Michael Sen and succeed Anke Schmidt, who has led the communications function since June 2025 and has decided to leave the company at her own request.“On behalf of the Management Board, I would like to express my sincere thanks to Anke Schmidt for her work and commitment. She has made an important contribution in a short period of time. We wish her all the best for her future endeavors”, says Michael Sen, CEO of Fresenius. “I am very pleased that Katrin Kerner and Christian Wagner will jointly assume this responsibility as a leadership team. Both have a deep understanding of the healthcare industry and are already actively shaping the strategic and cultural transformation of our company through #FutureFresenius. With their extensive experience in communications, finance, and corporate transformations at DAX-listed companies, they will further develop the communications function at Fresenius and continue to strengthen our brand.”Katrin Kerner has been with Fresenius since 2023 and has served as Head of CEO Relations since 2024. In this role, she prepares CEO briefings, coordinates strategic company positions, and manages global partnerships. Before joining Fresenius, she held several leadership positions in communications functions at Siemens, Siemens Healthcare (today Siemens Healthineers), and Siemens Energy, including Head of Employee Communications at Siemens and Head of Executive Messages at Siemens Energy. During this time, she was actively involved in the IPO of Siemens Healthineers and the spin-off of Siemens Energy. Katrin Kerner studied Economics at the Friedrich-Alexander University Erlangen-Nürnberg and International Management at the Turku School of Economics in Finland.Christian Wagner joined Fresenius in 2017, became Head of Corporate Finance in 2019, and has served as Head of Board Office since 2023. In this function, he plays a key role in steering and advancing Fresenius’s strategic direction. He is also responsible for Corporate Security. Before joining Fresenius, Christian Wagner worked in investment banking at Berenberg and at a subsidiary of Deutsche Bahn. He studied Finance at Goethe University Frankfurt and the Institut Supérieur du Commerce (ISC) in Paris, France.

    November 14, 2025 · Fresenius

  • Brief News

    Fresenius climbs to 2nd place in governance ranking

    The German Association for Financial Analysis and Asset Management (DVFA) Scorecard for Corporate Governance serves as an important benchmark for assessing governance standards among DAX 40 companies in Germany. Fresenius has reached 2nd place in this year’s ranking – a significant leap from last year and thus the largest climb of all companies evaluated. This recognition reflects the significant progress made to further strengthen the company’s governance structures as part of the #FutureFresenius strategy.

     

    November 14, 2025 · Fresenius

    Fresenius Q3/25: Disciplined execution drives continued strong performance – guidance raised

    Fresenius Q3/25: Disciplined execution drives continued strong performance – guidance raised

    November 05, 2025 · Fresenius

  • Brief News

    Fresenius simplifies sale process of Vamed's Austrian operations

    Sale in two independent steps simplifies and accelerates divestment of Vamed’s Austrian activities Fresenius and Porr signed an agreement today on the sale of Austrian project business and the thermal spas operations of VAMED Vitality WorldIn-depth talks ongoing with Strabag on sale of Vienna General Hospital (AKH Wien) operations business The healthcare group Fresenius is accelerating and simplifying the divestment of Vamed's Austrian activities by a sale in two independent steps. The original agreement to sell to an Austrian consortium consisting of the construction companies Porr and Strabag has now been replaced by a direct contract with Porr for the sale of the Austrian project business and the thermal spas operations of VAMED Vitality World. The new agreement is subject to regulatory approval. In-depth talks are also ongoing with Strabag regarding remaining parts of Vamed's Austrian activities – primarily the operations business of the Vienna General Hospital (AKH Wien). The sale of the Austrian activities is another step in Fresenius' structured exit from its investment company Vamed, enabling Fresenius to further increase focus on the ongoing progress of Fresenius Kabi and Fresenius Helios in line with #FutureFresenius.

     

    October 10, 2025 · Fresenius

    Brief News

    Fresenius receives Vizient® Awards for Supply and Service Excellence in the U.S.

    Fresenius Kabi, part of the global healthcare company Fresenius, announced today it has received two awards for supply and service excellence from Vizient®, the largest provider-driven healthcare performance improvement company in the U.S. The Supplier of the Year Awards recognize outstanding suppliers by category that support Vizient’s mission to strengthen providers’ delivery of better, more affordable care. “These awards from Vizient are an important acknowledgment of the company’s commitment to long-term, sustainable drug supply,” said Arun Verma, president, Fresenius Kabi USA and a member of the Executive Leadership Team at Fresenius Kabi AG. “The Vizient Supply Assurance award is especially gratifying as it recognizes our efforts to assure continuity of supply for essential medicines and technologies."

     

    September 25, 2025 · Fresenius Kabi

  • Brief News

    Key parameter for the 2026 DRG inflator for German hospitals set at 5.17%

    The rate of change, a key parameter for determining the price increase for the reimbursement of hospital treatments in 2026 in Germany, has been set at 5.17%. The change in hospital costs is the other parameter used in the annual determination of the reimbursement increase. The final DRG inflator should be determined at the latest by the end of the year.

     

    September 15, 2025 · Fresenius

    Fresenius successfully places bonds with a volume of 1 billion euros

    Fresenius successfully places bonds with a volume of 1 billion euros

    September 08, 2025 · Fresenius

  • Fresenius receives a €400 million EIB loan

    Fresenius receives a €400 million EIB loan

    This financing supports Fresenius's efforts to increase the availability of innovative medical products and biosimilars in the European Union and is a further step in the #FutureFresenius agenda.

    September 08, 2025 · Fresenius

All News Disclaimer
Publication Annual Report 2025

March 25, 2026
Bad Homburg, Germany

Publication Annual Report 2025

Consolidated Financial Statements and Management Report (IFRS)

Online Annual Report
Fresenius Annual Report 2025 Import (ICS)

Latest

Library

Entdecken Sie am heutigen Weltgesundheitstag, wie die Geschäftsbereiche von Fresenius Forschung und Entwicklung, neue Technologien und Patientenversorgung zusammenbringen, um dazu beizutragen, die Behandlungsergebnisse für Patientinnen und Patienten zu verbessern. 

Am 7. April ist der internationale Weltgesundheitstag, der 2026 unter dem Motto „Together for health. Stand with science.“ steht. Er stellt die Bedeutung wissenschaftlicher Erkenntnisse und Zusammenarbeit als Basis für Fortschritte in der Medizin und eine bessere Patientenversorgung in den Mittelpunkt.

Diese Fortschritte entstehen nicht zufällig. Sie sind das Ergebnis intensiver Forschung, dem stetigen Streben nach Innovationen und einer engen internationalen Zusammenarbeit von Wissenschaft, Industrie und klinischer Praxis. Diesem Anspruch folgt auch Fresenius. Viele unserer rund 175.000 Mitarbeitenden arbeiten über alle Segmente hinweg täglich daran, wissenschaftliche Erkenntnisse in konkrete Verbesserungen in der Diagnostik, bei Arzneimitteln und in der Patientenversorgung zu übersetzen. Prof. Dr. med. Ralf Kuhlen, Chief Medical Officer Corporate Development bei Fresenius, bringt es auf den Punkt: „Wir sind bestrebt, wissenschaftliche Erkenntnisse in bessere Versorgung umzusetzen – gemeinsam mit wissenschaftlichen Institutionen haben wir das Ziel, Behandlungen effizienter, sicherer, zuverlässiger und für mehr Patientinnen und Patienten zugänglich zu machen.“  

Vom Patientenpfad bis zum wissenschaftlichen Fortschritt bei Helios 

Einer dieser Patienten ist Benjamin Kaiser. Als er nach zwei Wochen anhaltender Bauchschmerzen seine Hausärztin aufsucht, rechnet er nicht mit einer Diagnose, die sein Leben innerhalb weniger Stunden grundlegend verändern würde. Doch in den folgenden Tagen bringt die Diagnostik Gewissheit: Es ist ein aggressives B-Zell-Lymphom. Es folgen belastende Untersuchungen und eine erste Immunchemotherapie. Doch nach sechs Zyklen zeigt sich: Der Tumor wächst weiter. Also müssen für den 37-Jährigen weitere Behandlungsmöglichkeiten in Betracht gezogen werden. Eine Standardbehandlung in dieser Situation ist die CAR-T-Zelltherapie. Zu diesem Zeitpunkt unterliegt die Therapie in Deutschland keinen Einschränkungen mehr. Da sie jedoch hoch spezialisiertes Fachwissen erfordert, wird die Therapie in der Regel nur in ausgewählten Kliniken durchgeführt; ein Grund, warum Benjamin Kaiser an das spezialisierte Behandlungszentrum am Helios Klinikum Berlin-Buch überwiesen wird. 

Hier in Berlin-Buch hat Benjamin Kaiser Zugang zu einer CAR-T-Zelltherapie, einer personalisierten Immuntherapie, bei der körpereigene Immunzellen genetisch verändert werden, um Krebszellen gezielt anzugreifen. Bei der Herstellung dieser Therapien können die Zellverarbeitungssysteme LOVO und Cue von Fresenius Kabi eine wichtige Rolle spielen, da sie das Waschen, Konzentrieren, Formulieren und finale Bereitstellen der Zellen automatisieren. Zuvor stabilisiert das Behandlungsteam unter der Leitung von Prof. Dr. Bertram Glaß, Head of Hematology and Oncology am Helios Klinikum Berlin-Buch, den Krankheitsverlauf mit Bestrahlung und Antikörpertherapie und schafft so die Voraussetzung für die Zelltherapie. 

Dass diese Therapie heute in Deutschland verfügbar ist, ist das Ergebnis internationaler klinischer Forschung und der aktiven Beteiligung unserer Kolleginnen und Kollegen von Helios. Das Team in Berlin-Buch war an der TRANSFORM-Studie beteiligt und ermöglichte Patientinnen und Patienten früh den Zugang zu dieser Behandlung. Seit 2019 werden hier regelmäßig CAR-T-Zelltherapien durchgeführt. Parallel untersuchen Forschende, wie sich der Einsatz in frühere Krankheitsphasen verlagern lässt, und analysieren europäische Registerdaten, um Therapien gezielter einzusetzen. 

Dr. Anna Ossami Saidy, Ärztin in Weiterbildung im Team von Prof. Glaß und Mitglied der europäischen Lymphom-Arbeitsgruppe, analysiert Daten aus dem Register der Europäischen Gesellschaft für Blut- und Knochenmarktransplantation (EBMT). „Erst durch die Auswertung einer großen Anzahl von Patientendaten können wir verstehen, welche Therapie für welchen Patienten am besten wirkt – und Behandlungen gezielt weiterentwickeln“, sagt sie. „Dafür brauchen wir aber immer die Kooperation der Patienten!“ Ihre Ergebnisse zeigen: Verschiedene CAR-T-Zellprodukte sind in vergleichbaren Fällen ähnlich wirksam – ein wichtiger Schritt hin zu individualisierten Therapieentscheidungen. Das Projekt wurde auf dem EBMT-Kongress 2026 ausgezeichnet. 

Für Benjamin Kaiser hat diese Forschung unmittelbare Folgen: Heute sind keine Tumorreste mehr nachweisbar. Er plant die Rückkehr in seinen Beruf, weiß aber, dass die Nachsorge entscheidend bleibt. Seine Bereitschaft, Daten für die Forschung zur Verfügung zu stellen, ist für ihn selbstverständlich. Eines wird deutlich: Fortschritt entsteht nicht nur im Labor, sondern auch durch Patientinnen und Patienten, die sich daran beteiligen. 

Von Fresenius Kabi vorangetriebene Forschung 

Während auf Intensivstationen täglich Entscheidungen getroffen werden, die das Wohlergehen von Patientinnen und Patienten betreffen, rückt bei Fresenius ein weiterer Faktor in den Fokus: die klinische Ernährung kritisch kranker Patientinnen und Patienten. Hier setzen Initiativen von Fresenius Kabi an – getragen von Forschenden und medizinischen Expertinnen und Experten, die das Ziel verfolgen, die Versorgung durch wissenschaftliche Erkenntnisse weiterzuentwickeln. 

Fresenius Kabi investiert in die nächste Generation Forschender. Im Rahmen unserer internationalen JUMPstart-Programme unterstützen wir junge Ärztinnen und Ärzte sowie Wissenschaftlerinnen und Wissenschaftler weltweit mit Mentoring und Schulungen. Ziel ist die Entwicklung eigener Studien – von der ersten Idee bis zur Umsetzung. So entsteht ein wachsendes Netzwerk engagierter Forschender, das neue Impulse für die medizinische Ernährung setzt, etwa in der Intensivmedizin oder bei chronischen Erkrankungen. 

Darüber hinaus unterstützen Teams von Fresenius Kabi aus dem Bereich Medical Clinical & Scientific Affairs in Zusammenarbeit mit der European Society of Intensive Care Medicine (ESICM) konkrete Forschungsprojekte in der Ernährungstherapie. Mit dem ESICM-Fresenius Kabi Medical Nutrition Research Grant werden Studien finanziert, die sich mit zentralen Versorgungsfragen befassen, wie beispielsweise Stoffwechsel, Nährstoffbedarf und wirksamen Ernährungsstrategien für kritisch kranke Patientinnen und Patienten. Fellowships und Schulungsprogramme unterstützen junge Intensivmedizinerinnen und -mediziner, neue Erkenntnisse direkt in den klinischen Alltag zu übertragen. 

Die beiden Programme greifen ineinander: Während die ESICM-Kooperation aktuelle Forschung in die Anwendung bringt, schafft JUMPstart die Grundlage für die Versorgung von morgen. Beide Initiativen haben das Ziel, wissenschaftliche Erkenntnisse zu erlangen, sie schneller in die klinische Praxis zu überführen und damit die Versorgung kritisch und chronisch kranker Menschen zu verbessern.   

Zudem zeigen Initiativen wie das EASYGEN-Konsortium, wie die Zusammenarbeit von Industrie, Kliniken und Wissenschaft neue Therapieansätze vorantreiben kann, beispielsweise indem daran gearbeitet wird, eine dezentrale Herstellung von CAR-T-Zelltherapien zu ermöglichen und den Zugang zu diesen Therapien für Patientinnen und Patienten zu verbessern.  „Fresenius Kabi unterstützt die EASYGEN-Initiativen durch die Entwicklung und den Einsatz der nächsten Generation des Cue Zellverarbeitungssystems, das eine neuartige Methode der T-Zellenselektion für die in sich geschlossene Herstellung patienteneigener CAR-T-Zellen in großen Mengen nutzt. Dadurch wird eine duale Systemintegration ermöglicht, die durch die Zusammenarbeit mit TQ Therapeutics vorangetrieben wird“, erklärt Paige Bothwell, Forschungswissenschaftlerin bei Fresenius Kabi Research Technologies. Das Konsortium ist ein Zusammenschluss von 18 Organisationen und umfasst – neben Fresenius Kabi – Fresenius, Helios und Quirónsalud als aktive Partner. 

Parallel dazu konzentrieren sich die Aktivitäten von Fresenius Kabi im Bereich Pharma auf die Bereitstellung von lebenswichtigen Medikamenten. Dazu gehören i. v. Arzneimittel und Infusionslösungen, die ein wesentlicher Bestandteil vieler Behandlungsprotokolle sind, insbesondere in der Onkologie und der Intensivmedizin. 

Ein zentraler Pfeiler unseres Geschäftsbereichs Biopharma ist die Entwicklung von Biosimilars – biologischen Arzneimitteln, die in Bezug auf Qualität, Sicherheit und Wirksamkeit den Referenzprodukten entsprechen und gleichzeitig dazu beitragen, die Kosten in der Gesundheitsversorgung zu senken. Durch ein vertikal integriertes Modell von der Forschung und Entwicklung bis zum Vertrieb möchte Fresenius Kabi seine Biosimilar-Versorgungskette widerstandsfähig und zuverlässig machen. Auf diese Weise wird wissenschaftliche Innovation in einen breiteren Zugang zu wirksamen Therapien und in nachhaltigere Gesundheitssysteme umgesetzt.  

 

Subscribe to